The article states that Phase II trials are yet to start, so no proof yet it works. In a somewhat related study, involving immunization with myelin, quote, "the team was able to isolate a human autoantibody, which they labeled monoclonal HIgM22. Unlike industry-synthesized antibodies, HIgM22 is a naturally occurring immunoglobulin molecule that is primitive in evolutionary terms and is the body's first and most rapid response, often referred to as the innate immune response.
HIgM22 was sequenced into a recombinant form (rHIgM22) in Dr. Pease's laboratory and was found to be as effective as its serum-derived counterpart in inducing remyelination in Theiler's virus-infected mice. The results showed that 60 to 80 percent of the animals' lesions were repaired."
"That 60 to 80 percent repaired" sounds wonderful. The article can be found at http://www.mayoclinic.org/medicalprofs/ ... u0804.html